⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
Rosiglitazone (PPAR-γ Agonist)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-05-28 — Rosiglitazone alleviates Parkinson’s disease phenotypes of Drosophila via dCTP-mediated inhibition of AGE-RAGE pathway.: Drosophila PD model: rosiglitazone and its elevated downstream metabolite dCTP rescued motor and lifespan phenotypes, reduced brain lipid-droplet accumulation, and restored mitochondrial quality control via inhibition of the over-activated AGE-RAGE/EGR1 pathway (metabolomic + transcriptomic support; fly-model only). [animal-model] (novelty: 3)
Open questions
Related
Contributing findings
Rosiglitazone alleviates Parkinson's disease phenotypes of Drosophila via dCTP-mediated inhibition of AGE-RAGE pathway.
28-may-2026
novelty 3
per-area 3
strengthens